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Abstract: The study was conducted to evaluate the immunogenicity and protective efficacy of a DNA vaccine against foot-and-mouth
disease virus (FMDV). Genes encoding the P1, 2A, 3C of FMDV O/China99 and bovine IFN-α were cloned into pcDNA3.1 (+)
expression vector under CMV promoter and FMDV IRES control, respectively. The recombinant plasmids were administered to
guinea pigs by intramuscular injection with mono- or bicistronic expression plasmids and aurintricarboxylic acid (ATA). After 2
sequential vaccinations with plasmid DNA, all of guinea pigs were challenged with 100 ID50 FMDV O/China99. Anti-FMDV antibodies
were detected by ELISA and neutralization assay, and the phenotyping of T-cell subpopulation in the peripheral blood were
performed by flow cytometry. Vaccination of guinea pigs with mono- or bicistronic expression plasmids induced humoral and cellular
immune responses to FMDV antigens. In the challenge test, a part of the animals were protected against the challenge of a virulent
virus. This study demonstrates that the delivery of FMDV antigens via bicistronic vectors is feasible. Further experimentation with
bicistronic delivery systems is required for the optimization and refinement of DNA vaccines to effectively prime protective immune
responses against foot-and-mouth disease (FMD).
Key Words: Foot-and-mouth disease virus, DNA vaccine, aurintricarboxylic acid, IFN-α, Bicistron expression vector

Introduction
FMDV is a picornavirus that affects artiodactyls,
especially cattle and swine. The virion consists of a singlestrand, positive-sense RNA genome packaged in an
icosahedrally symmetric capsid composed of 60 copies
each of 4 structural proteins, VP1 to VP4. FMD is one of
the most contagious animal diseases. Control of the
disease in endemic areas is carried out with inactivated
whole virus vaccines that induce a serotype-restricted,
short-lived protection, making frequent revaccination a
prerequisite in control campaigns (1). Furthermore, the
presence of residual live viruses in these inactivated
vaccines and the escape of viruses from vaccine
production plants have been implicated in FMD outbreaks
(2).
Direct injection of DNA into animals is a novel and
promising method for delivering specific antigens for

immunization. Endogenous expression of antigen from
DNA introduced into host cells leads to the production of
structurally and conformationally relevant molecules of
the antigen that are able to activate specific immunity.
Plasmid DNA vaccination can protect against many viral,
fungal and parasitic diseases in different animal models
(3-5). However, a general problem with plasmid DNA is
that the vaccines alone are often poorly immunogenic. In
recent years, there has been great interest in modulating
the immune responses by inoculating with vectors
encoding cytokines or other costimulatory molecules and
antigens.
Type I interferon (IFN-α) not only play a key role in
defense against pathogens but also have potent
immunomodulatory activities (6,7). Chinsangaram et al.
(8) also demonstrated that IFN-α of porcine or bovine
origin and porcine IFN-β could exert an inhibitory effect

* E-mail: liukey@public.lz.gs.cn

85

A Bicistronic DNA Vaccine Containing Gene of FMDV and Bovine IFN-α Can Prime Humoral and Cellular Immune Responses of Guinea Pigs

on FMDV in cells from homologous and heterologous
species. Therefore, we select bovine IFN-α as a native
adjuvant and hope it can also exert its immune function in
cattle and pig.
On the other hand, nuclease activity present within
tissues contributes to the rapid clearance of injected DNA
and therefore may reduce the transfection activity of
directly injected transgenes. Aurintricarboxylic acid (ATA)
is a general inhibitor of nucleases (9). Glasspool-Malone
et al. (10) found that intratracheal administration of a
nuclease inhibitor (ATA) with naked DNA (0.5 µg ATA/g
body weight) enhanced direct transfection efficacy in
macaque lung by over 86-fold and in mouse lung by over
54-fold. According to these investigations, we used the
ATA in DNA direct injection of guinea pigs in order to
enhance direct transfection efficacy of DNA vaccine in vivo
and immune response against FMDV antigen.
Bicistronic vectors as a kind of multivalent DNA
vaccine expression systems may enable more efficient
delivery of DNA vaccine and promote immune
responses. Bicistronic plasmids utilize an internal
ribosome entry site (IRES) that is placed between 2
coding regions and can allow ribosomes to attach to
mRNA, and then the downstream coding sequence of
IRES can be translated, while the upstream sequence is
translated by cap-dependent mechanisms (11,12).
Presently, viral bicistronic and polycistronic vectors are
widely used in the research of cancer gene therapy.
Nonviral bicistronic vector is also used as a DNA vaccine
for several viruses (13,14). But so far, there has been
no bicistronic or polycistronic DNA vaccine in FMD gene
vaccination. So, according to that bicistronic delivery of
DNA vaccines may have the potential to enhance the
ability of first-generation DNA vaccines to prime an
immune response prior to a FMDV infection. We
attempted to analyze the immune response induced in
guinea pigs by a recombinant bicistronic DNA vaccine
pcDNA/PIF that expresses the precursor polyprotein
(P1), non-structural protein 3C which ensures the
processing of the polyprotein precursor to produce 3
FMDV capsid proteins (VP0, VP3, VP1), and bovine IFNα. The effect of bicistronic immunization of guinea pigs
on protection after FMDV O/China99 challenge was also
assessed.
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Materials and Methods
Construction of recombinant plasmid
The bicistronic DNA vaccine pcDNA/PIF was
constructed by a 3-way ligation of IFN, IRES and
P12X3C. In brief, the bovine IFN-α gene was obtained
from pcDNA3.1/IFN (15) by PCR technology and the
EcoRI site and XhoI site were introduced into 5’ end and
3’ end of IFN fragment respectively. FMDV IRES gene
with BamHI and EcoRI was obtained from pGEM/IRES
(unpublished data) by PCR technology. The gene P12X3C
was obtained from pcDNA3.1/P12X3C (16) by PCR
technology and SpeI and BamHI restriction sites were
introduced at each end. Meanwhile, the plasmid
pcDNA3.1 (+) (Invitrogen) was digested by SpeI and XhoI
endonucleases. Then the digested products were ligated
and the resultant plasmid pcDNA/PIF was further
characterized by restriction endonuclease analysis, PCR
amplification, and sequencing to authenticate the DNA
sequences.
Immunization
All guinea pigs were immunized as described
previously (16).
Group A: FMD conventional vaccine; Group B:
pcDNA/P12X3C; Group C: pcDNA/P12X3C+pcDNA/IFN;
Group D: pcDNA/PIF; Group E: pcDNA3.1(+); Group F:
DPBS.
Measurement of anti-FMDV antibodies level
Blood samples were analyzed by indirect ELISA as
previously described (16).
Detection of specific neutralizing antibodies
Micro-neutralization assays were performed as
previously described (16).
Flow cytometry analyses
For the phenotype of T-cell subpopulation in the
peripheral blood by flow cytometry, single-labeling
methods were employed for defining different
subpopulations. To this end, the following mouse
monoclonal antibodies (mAb) reactive with guinea pig
leukocyte cluster of differentiation (CD) antigens were
used: mouse anti guinea pig CD4 (Serotec) and mouse
anti guinea pig CD8 (Serotec). The blood cells (100 µl)
were incubated with 10 µl of fluorescein isothiocyanate
6
(FITC)-conjugated mouse anti guinea pig IgG per 10
leukocytes for 30 min at room temperature in the dark.
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Controls without any reagents were included for each
animal. In each test, 10,000 cells were counted using a
FACScan flow cytometer (Becton Dickinson) for data
acquisition, and data were analyzed using the CellQuest
software (Becton Dickinson).
Challenge of animals
All guinea pigs were challenged by footpad injection of
0.2 ml 100 ID50 FMDV O/China99 (offered by State Key
Laboratory of Veterinary Etiological Biology and Key
Laboratory of Animal Virology of Ministry of Agriculture,
Lanzhou Veterinary Research Institute, China) at the third
week after secondary vaccination. All guinea pigs were
examined for characteristic FMD lesions on the footpad
for 7 days after challenge. The lesion appeared at the site
of virus injection, without spreading to other feet, was
referred to as indicator of partial infection and on both
back sole as indicator of whole infection (17).

Results
Specific antibody response to FMDV
As shown in Figure 1, specific antibody of animals
immunized with conventional vaccine and recombinant
plasmids emerged after the first vaccination, and

subsequently these antibodies decreased in some sort.
But except for guinea pigs of group A, the antibody level
of guinea pigs in group B, C, D, which were increased
after the second vaccination, was almost no more than
that induced at the second week after the first vaccination
and held a steady level on the whole. The antibody level
of control group (group E and group F) did not change
after inoculation.
Induction of neutralizing antibodies after DNA
immunization
Neutralizing antibody determinations were performed
in serum sera sampled before (day 0) and after
vaccination (days 14, 28, 42, and 56). As shown in
Figure 2, all guinea pigs of the experimental group
developed neutralizing antibody after the first
vaccination. Except for guinea pigs in group A
(immunized with FMDV conventional vaccine),
neutralizing antibody titers of other groups decreased at
the first week after the second vaccination. Subsequently,
the neutralization titers of all of guinea pigs increased
(group B, group C, and group D) or maintained (group
A).
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Figure 1. Alternation in FMDV antibody levels of immunized guinea
pigs. Animals were immunized with different reagents at
week 0 and 4. Sera were collected at the indicated times, and
antibody levels were measured by ELISA at 1:16 dilution and
indicted by OD value. The result was obtained from average
of 3 sera in each group.
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Figure 2. Neutralizing antibody was measured in 6 groups of animals.
Serum samples were taken on day 0, day 14, day 28, day
42, and day 56 before and after vaccination. Titers are
expressed as log10TCID50/ml measured on BHK-21 cells and
calculated by the Spearman-Karber method. The result was
obtained from average of 3 sera in each group. The results
of group E and group F are intersection of abscissa at Ycoordinate.
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The phenotyping change of T-cell subpopulation of
guinea pigs vaccinated with pcDNA/PIF
Flow cytometric analysis (Figure 3) showed that, in all
+
+
tested groups, the ratio of both CD4 and CD8
peripheral blood T-cell subpopulation increased
significantly in comparison with negative controls (group
E and group F) after prime immunization, but this radio
decreased at the forth week. And the ratio of CD4+ and
CD8+ peripheral blood T-cell subpopulation increased
further at the second week after boost immunization,
which is similar to the change of ratio after first
immunization. Subsequently this ratio decreased at the
forth week.
Protection result of guinea pigs
In challenge test, all guinea pigs were subcutaneously
and intradermally challenged with 0.2 ml 100 ID50 of live
virus on left rear foot at the fourth week after the second
vaccination. The positive (group A) and negative (group E
and group F) controls followed expectations, yielding
protection or disease, respectively (Table). The negativecontrol animals and blank-control animals that were not
protected developed vesicles in both rear feet at day 2
after challenge.

1.6

Discussion
Vaccination continues to be the most successful
procedure for preventing infectious diseases in animals
and humans. The development of new-generation vaccine
systems to prevent FMD is needed to overcome the
disadvantages of the currently used inactivated whole
virus vaccines. The cotransfer of different genes into a
cell can be achieved by mixing different plasmids, but
gene expression from such mixtures of plasmids is not
balanced. The reason is that the uptake of DNA is a
matter of statistical variation; the lifetime of different
mRNAs varies depending on the nature of the transcript.
Even if the same promoters/enhancers are used on
different plasmids, protein expression of different genes,
and thereby antigen presentation, will vary significantly.
This uncoupled expression could cause problems in DNA
vaccination in which controlled coexpression of different
antigens is an essential prerequisite for the construction
of a polyvalent vaccine (18).
The discovery of cap-independent translational
initiation elements (IRES, internal ribosomal entry sites)
allowed the construction of bi- or polycistronic expression
plasmids where several proteins are separately translated
from one mRNA (19). Efficient IRES elements have been
identified in picornaviruses and other viruses (20-22).

CD4/CD8
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0.6
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0
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groupC

The first vaccination (28 days)

groupD
groupE
groupF
The first vaccination (14 days)
The second vaccination (42 days)

The second vaccination (56 days)
Figure 3. The phenotype change of T-cell subpopulation of guinea pigs vaccinated. This
test was performed at week 2 (day 14), week 4 (day 28), week six (day 42)
and week 8 (day 56) post vaccination.
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Table. Protection of guinea pigs from viral challenge.
Serial number
of guinea
pigs
Protection

Severity of
Symptoms

Rate of protection(%)

Group A*

Group B

Group C*

Group D

Group E

Group F

1

Total

Total

Total

Total

None

None

2

Total

Total

Total

Total

None

None

3

Total

Total

Total

Total

None

None

4

Total

Total

Total

Total

None

None

5

Total

None

Total

Total

None

None

6

NT

partial

NT

None

None

None

1

None

None

None

None

Severe

Severe

2

None

None

None

None

Severe

Severe

3

None

None

None

None

Severe

Severe

4

None

None

None

None

Severe

Severe

5

None

Severe

None

None

Severe

Severe

6

NT

Mild

NT

Severe

Severe

Severe

100(5/5)

66.7(4/6)

100(5/5)

83.3(5/6)

0(0/6)

0(0/6)

* One guinea pig died. Severity of symptoms was based on daily monitoring, completed on day 7 post-challenge, and is scored as: none, no lesions on
both rear feet; mild, lesions on one rear foot; severe, lesions on both rear feet. Protection was scored by the severity of lesions: total protection
was defined as complete absence of lesions; partial protection was scored as lesions restricted on one rear foot; none was lesions on all of rear feet.
Rate of protection (%) =Number of guinea pigs no lesions on both rear feet/Total number of guinea pigs.

Because foot-and-mouth disease virus IRES provides hightiter bicistronic vectors with high-level 2-gene expression
(23), we selected the IRES element of FMDV to initiate the
translation of proteins (IFN) downstream in this study.
In this communication, we describe the construction
of a plasmid carrying FMDV sequences. The advantage of
such a construct is its ability to express and process all
structural proteins to form an empty viral capsid that will
be a superior immunogenic entity as it can initiate the
immune system better than separate viral proteins like
VP1 itself. It was observed that viral structural proteins
have the tendency to induce the humoral response,
whereas nonstructural proteins seem to be more effective
in inducing the cellular immune system (17). Thus, this
particular construct was built in mind to express a
mixture of both structural and nonstructural viral
proteins.
As the result showed, the FMDV antibodies were
induced after the first immunization but only the FMDV
antibodies of guinea pigs vaccinated with FMD

conventional vaccine increased significantly after the
second immunization. Although the FMD antibodies of
guinea pigs in other groups (except for group E and group
F) also increased, it is not significant in comparison with
that of guinea pigs in group A. This result is similar to
previous studies (15,16). The neutralization antibody
titers showed the same diversification after the prime
immunization as the specific antibody titers; however,
neutralizing antibody titers increased after boost
immunization. It can be postulated that the protein
expressed after boost immunization is neutralized by
antibodies induced after prime immunization;
subsequently enough protein is expressed by plasmid DNA
and this induces more distinct neutralizing antibody
response than prime immunization. It is reasoned that the
DNA plasmid needs the process of adsorption, entrance,
translation, and expression when inoculated to animal, so
it can be assumed that DNA vaccine stimulates the immune
system to produce antibodies for a longer time than
conventional vaccine obtained from organism antigen.
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But on the other hand, it is thought that the dosage
of DNA vaccine is not enough and need to be improved.
Additionally, a method to deliver adequate amounts of the
desired gene resulting in adequate expression of the
encoded protein is needed.
In general, expression of CD4 and of CD8 also defines
2 major functional subpopulations of T lymphocytes.
+
CD4 T cells generally function as T helper (TH) cells and
are class-II restricted; CD8+ T cells generally function as T
cytotoxic (TC) cells and are class-I restricted. Thus the
ratio of TH to TC cells in a sample can be approximated
by assaying the number of CD4+ and CD8+ T cells. This
ratio is comparatively fixed in normal peripheral blood,
but diseases or other disorders may significantly alter it.
We used flow cytometric analysis to evaluate the T-cell
immune response induced by plasmid DNA. Flow
cytometric analysis showed that the ratio of CD4+ and
CD8+ lymphocytes increased firstly after prime
immunization or boost immunization and then decreased.
This situation is consistent with changes in the level of
specific antibody and neutralizing antibody responses. It
illuminated that DNA vaccine is inclined to mainly induce
CD4+ lymphocytes differentiate firstly and then CD8+
lymphocytes. This result further confirmed mechanism of
T-cell immune response induced by DNA vaccine once
again (24).
Combined with the results of FMDV specific and
neutralizing antibody responses, it seems that IFN-α did
exert its adjuvant function unsatisfactorily, especially, in
immune response induced by bicistronic plasmid
pcDNA/PIF. According to the literature (25), we presume
that the IRES is not optimal for driving translation and
expression of IFN-α and the quantity of IFN-α expressed
is too little to exert its adjuvant function. So it will be
attempted to construct a bicistronic plasmid in which
gene of IFN-α can be translated upstream of IRES and
compare the immune enhancement with the bicistronic
plasmid reported in this study. Another explanation could
be low-level transfection of plasmid DNA in vivo, which
leads to low-level expression of antigen carried by
recombinant plasmid. So much more work might improve
the efficiency of this approach including optimize plasmid,
dosage of DNA vaccine, immune programme, and so on.
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Consistent with our expectation, guinea pigs
inoculated with plasmid pcDNA/PIF were partially
protected from virulent virus challenge. It is supposed
that the size of plasmid pcDNA/PIF is larger than that of
pcDNA/P12X3C and pcDNA/IFN, which reduced the
transfection efficiency of plasmid in vivo. However, the
guinea pigs inoculated with pcDNA/P12X3C were
protected partially in comparison with the guinea pigs
coimmunized with pcDNA/P12X3C and pcDNA/IFN. It is
reasoned that bovine IFN-α gene in pcDNA/IFN can be
expressed more efficiently than that of pcDNA/PIF and
then exerts its adjuvant function in coimmunization group
with pcDNA/P12X3C and pcDNA/IFN more markedly than
that of group immunized with pcDNA/PIF, which can also
be revealed from results of humoral and cellular immune
response.
Although guinea pigs immunized with plasmid
pcDNA/PIF were not protected totally in comparison with
guinea pigs coimmunized with pcDNA/P12X3C and
pcDNA/IFN, the level of specific antibody and
neutralization antibody as well as extent of T-cell immune
response showed no significant difference from that of
guinea pigs coimmunized with pcDNA/P12X3C and
pcDNA/IFN. So taken into account the usage of DNA
vaccine, bicistronic constructs are more convenient than
coimmunization of plasmid DNA.
Taken together, the results of this paper indicate that
bicistronic vectors can induce humoral immune response
as efficiently as monocistronic constructs or
coimmunization of monocistronic constructs. It suggested
that bicistronic constructs thus offer a novel approach for
the design of FMD polyvalent vaccines that efficiently
induce humoral and cellular immune responses and
exploit new ways for FMD genetic immunization.
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